Tissue distribution and elimination of [14C]apixaban in rats

Drug Metabolism and Disposition

Volumn 39, Issue 2, 2011, Pages 256-264

  Wang, Lifei ^a   He, Kan ^a   Maxwell, Brad ^a   Grossman, Scott J ^a   Tremaine, Larry M ^b   Humphreys, W Griffith ^a   Zhang, Donglu ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; CARBON 14;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG MILK LEVEL; DRUG TISSUE LEVEL; DRUG URINE LEVEL; FEMALE; FETUS; GASTROINTESTINAL TRACT; HARDER GLAND; HEART; HYPOPHYSIS; ISOTOPE LABELING; KIDNEY CORTEX; LACTATION; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE; NONHUMAN; PANCREAS; PLASMA CONCENTRATION-TIME CURVE; PREGNANCY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RAT; SALIVARY GLAND; SINGLE DRUG DOSE; SPLEEN; THYMUS; TISSUE DISTRIBUTION; WHOLE BODY AUTORADIOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; CARBON RADIOISOTOPES; FECES; FEMALE; FIBRINOLYTIC AGENTS; MALE; MATERNAL-FETAL EXCHANGE; METABOLIC CLEARANCE RATE; MILK; PREGNANCY; PYRAZOLES; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

RATTUS;

EID: 79251511891     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036442     Document Type: Article

References (34)

1. Alcorn J and McNamara PJ (2002) Acyclovir, ganciclovir, and zidovudine transfer into rat milk. Antimicrob Agents Chemother 46:1831-1836.
2. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, et al. (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119:2877-2885.
3. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, and de Vries EG (2000) The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 26:449-462.
4. Bendayan R, Lee G, and Bendayan M (2002) Functional expression and localization of Pglycoprotein at the blood brain barrier. Microsc Res Tech 57:365-380.
5. Botticelli Investigators, Writing Committee, Buller H, Deitchman D, Prins M, and Segers A (2008) Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 6:1313-1318.
6. Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, and Staud F (2006) Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo. Clin Exp Pharmacol Physiol 33:58-65.
7. Ceckova-Novotna M, Pavek P, and Staud F (2006) P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol 22:400-410.
8. Cisternino S, Mercier C, Bourasset F, Roux F, and Scherrmann JM (2004) Expression, upregulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 64:3296-3301. (Pubitemid 38581436)
9. Cooray HC, Blackmore CG, Maskell L, and Barrand MA (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13:2059-2063.
10. Demeule M, Régina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, Moghrabi A, and Béliveau R (2002) Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 38:339-348.
11. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
12. Gerk PM, Oo CY, Paxton EW, Moscow JA, and McNamara PJ (2001) Interactions between cimetidine, nitrofurantoin, and probenecid active transport into rat milk. J Pharmacol Exp Ther 296:175-180.
13. Golden PL and Pollack GM (2003) Blood-brain barrier efflux transport. J Pharm Sci 92:1739-1753.
14. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed., Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
15. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, and Schinkel AH (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127-129.
16. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
17. Kaiser B (2002) Factor Xa - a promising target for drug development. Cell Mol Life Sci 59:189-192.
18. Lankas GR, Wise LD, Cartwright ME, Pippert T, and Umbenhauer DR (1998) Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 12:457-463. (Pubitemid 29110878)
19. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, and Deitchman D (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5:2368-2375.
20. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
21. Mann KG, Brummel K, and Butenas S (2003) What is all that thrombin for? J Thromb Haemost 1:1504-1514.
22. McNamara PJ, Burgio D, and Yoo SD (1992) Pharmacokinetics of cimetidine during lactation: species differences in cimetidine transport into rat and rabbit milk. J Pharmacol Exp Ther 261:918-923.
23. McNamara PJ, Meece JA, and Paxton E (1996) Active transport of cimetidine and ranitidine into the milk of Sprague Dawley rats. J Pharmacol Exp Ther 277:1615-1621.
24. Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, et al. (2007) Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6, 7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50:5339-5356.
25. Polgar O, Robey RW, and Bates SE (2008) ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 4:1-15.
26. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, et al. (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74-81.
27. Romero JJ, Cañas R, and Baldwin RL (1975) A technique for estimating milk production in rats. J Nutr 105:413-420.
28. Samama MM (2002) Synthetic direct and indirect factor Xa inhibitors. Thromb Res 106:V267-V273.
29. Shantsila E and Lip GY (2008) Apixaban, an oral, direct inhibitor of activated factor Xa. Curr Opin Investig Drug 9:1020-1033.
30. 14C]L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative wholebody autoradiography. Drug Metab Dispos 30:1164-1169.
31. Syme MR, Paxton JW, and Keelan JA (2004) Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 43:487-514. (Pubitemid 38858303)
32. Walenga JM, Jeske WP, Hoppensteadt D, and Fareed J (2003) Factor Xa inhibitors: today and beyond. Curr Opin Investig Drugs 4:272-281.
33. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, Luettgen JM, and Knabb RM (2008) Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 6:820-829.
34. 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 37:1738-1748.